SCOPUS 정보 검색 플랫폼

Nature Clinical Practice Rheumatology

Volumn 5, Issue 2, 2009, Pages 78-79

Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA

(1) van den Hout, Wilbert B a

a LEIDEN UNIVERSITY MEDICAL CENTER (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

ARTICLE; BONE DENSITY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG COST; DRUG MANUFACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOME CARE; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PATENT; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; VALIDATION PROCESS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOLOGIC FACTORS; QUALITY-ADJUSTED LIFE YEARS;

EID: 59849125510 PISSN: 17458382 EISSN: 17458390 Source Type: Journal
DOI: 10.1038/ncprheum0985 Document Type: Article

Times cited : (7)

References (9)

1
- 33845482745
- Chen YF et al. (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10: Iii-iv, xi-xiii, 1-229
- Chen YF et al. (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10: Iii-iv, xi-xiii, 1-229

2
- 54249154828
- Economic evaluation of health interventions
- Drummond M et al. (2008) Economic evaluation of health interventions. BMJ 337: A1204
- (2008) BMJ , vol.337
- Drummond, M.¹

3
- 0041807885
- What is the price of life and why doesn't it increase at the rate of inflation?
- Ubel PA et al. (2003) What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163: 1637-1641
- (2003) Arch Intern Med , vol.163 , pp. 1637-1641
- Ubel, P.A.¹

4
- 41849090784
- The validity and responsiveness of generic utility measures in rheumatoid arthritis: A review
- Harrison MJ et al. (2008) The validity and responsiveness of generic utility measures in rheumatoid arthritis: A review. J Rheumatol 35: 592-602
- (2008) J Rheumatol , vol.35 , pp. 592-602
- Harrison, M.J.¹

5
- 42449136231
- Contempory prevalence and incidence of work disability associated with rheumatoid arthritis in the US
- Allaire S et al. (2008) Contempory prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum 59: 474-480
- (2008) Arthritis Rheum , vol.59 , pp. 474-480
- Allaire, S.¹

6
- 59849128914
- Cost-utility analysis of treatment strategies in patients with recent onset rheumatoid arthritis
- in press
- Van den Hout WB et al. Cost-utility analysis of treatment strategies in patients with recent onset rheumatoid arthritis. Arthritis Rheum, in press
- Arthritis Rheum
- Van den Hout, W.B.¹

7
- 33846847629
- Work disability in rheumatic diseases
- Yelin E (2007) Work disability in rheumatic diseases. Curr Opin Rheumatol 19: 91-96
- (2007) Curr Opin Rheumatol , vol.19 , pp. 91-96
- Yelin, E.¹

8
- 37149040084
- It is the best of times; it is the worst of times: Is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues
- O'Dell JR (2007) It is the best of times; it is the worst of times: Is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues. Arthritis Rheum 56 3884-3886
- (2007) Arthritis Rheum , vol.56 , pp. 3884-3886
- O'Dell, J.R.¹

9
- 13444259348
- Cost-effectiveness analysis: Out of touch with clinical reality?
- Maetzel A (2005) Cost-effectiveness analysis: Out of touch with clinical reality? Arthritis Rheum 53: 3-4
- (2005) Arthritis Rheum , vol.53 , pp. 3-4
- Maetzel, A.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.